United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2012_register executive 2012-05-03 article Notices D09002ee1c7fd11b2 D09002ee1c7fd1219 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to ODIN Biotech, a Texas corporation, having a place of business in Dallas, Texas, to practice the inventions embodied in the patents and patent applications belonging to the patent family having HHS Reference Number E-008-2004/0. The exclusive license is one which qualifies under the Start-Up License Agreement program which is in place from October 1, 2011 through September 30, 2012. Specific details regarding the individual patents or patent applications which belong to this patent family are set forth in the table below: 77 FR 26304 https://www.govinfo.gov/app/details/FR-2012-05-03/2012-10636 2012-10636 fr03my12-77 4140-01-P https://www.govinfo.gov/app/details/FR-2012-05-03/2012-10636 https://www.govinfo.gov/content/pkg/FR-2012-05-03/html/2012-10636.htm https://www.govinfo.gov/content/pkg/FR-2012-05-03/pdf/2012-10636.pdf 1 p. 26304 26304 77 FR 26304 Prospective Grant of Exclusive License: Development of Ocular Therapeutics Utilizing the Peptide C16Y and Related Peptides; Federal Register Vol. 77, Issue NOTICE 2012-10636 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2012-05-18 4140-01-P 2012-10636 Notice.

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to ODIN Biotech, a Texas corporation, having a place of business in Dallas, Texas, to practice the inventions embodied in the patents and patent applications belonging to the patent family having HHS Reference Number E-008-2004/0. The exclusive license is one which qualifies under the Start-Up License Agreement program which is in place from October 1, 2011 through September 30, 2012. Specific details regarding the individual patents or patent applications which belong to this patent family are set forth in the table below:

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 18, 2012 will be considered. Requests for copies of the patent application(s), inquiries, AND comments relating to the contemplated exclusive license should be directed to: Susan S. Rucker, JD, CLP, Senior Advisor for Intellectual Property Transactions, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435- 4478; Facsimile: (301) 402-0220; Email: ruckersu@mail.nih.gov. Prospective Grant of Exclusive License: Development of Ocular Therapeutics Utilizing the Peptide C16Y and Related Peptides , ruckersu@mail.nih.gov Vol. 77, no. 86 Office of the Federal Register, National Archives and Records Administration 2012-05-03 continuing daily deposited born digital 272 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2012-05-03 P0b002ee18261278c 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr03my12 https://www.govinfo.gov/app/details/FR-2012-05-03 https://www.govinfo.gov/content/pkg/FR-2012-05-03/pdf/FR-2012-05-03.pdf https://www.govinfo.gov/content/pkg/FR-2012-05-03/xml/FR-2012-05-03.xml fdlp 26149 26411 DGPO 2012-05-03 2024-06-03 FR-2012-05-03 machine generated eng FR FR-2012-05-03 77 86